Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ABB S3 + ABB C22
- Development stage
- Unknown
- Lead developer
- Abbiotek Health
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
ABB S3 + ABB C22 refers to a postbiotic yeast-based combination product, where ABB C22 is a blend containing the specific strain Saccharomyces boulardii ABB S3. Developed by ABbiotek Health, ABB C22 is composed of three tyndallized (heat-killed) yeast strains: Saccharomyces boulardii ABB S3, Saccharomyces cerevisiae ABB S6 (which is enriched with zinc), and Kluyveromyces marxianus ABB S8. The product is designed for the treatment and prevention of acute diarrhea in children and adults, and has been investigated for managing diarrhea-related inflammation in the elderly. Its multi-mechanistic approach includes enhancing gut barrier function, providing anti-inflammatory effects, protecting against rotavirus infection, and modulating the gut microbiome. It also serves as a source of highly bioavailable zinc, a micronutrient recommended by the WHO for diarrhea management.
- Other names
- postbiotic blendtyndallized yeast strains
Beyond the preview
Go deeper on ABB S3 + ABB C22.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ABB S3 + ABB C22.